
Opinion|Videos|May 15, 2024
In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs
Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
5

























